Bayer acquires rights in Puhe BioPharma cancer drug candidate

FRANKFURT (Reuters) -Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China’s Puhe BioPharma.

Bayer, which did not disclose financial terms, said it had enrolled the first patient to test the drug, a PRMT5 inhibitor that selectively targets MTAP-deleted tumors, in the first phase of clinical trials.

(Reporting by Ludwig Burger, editing by Rachel More)